Collegium Pharmaceutical Inc. (COLL) experienced a substantial surge of 5.63% in its stock price on Friday, driven by the company's impressive fourth quarter 2024 earnings performance and promising growth prospects unveiled during the earnings call.

The company reported record net product revenues of $181.9 million for Q4, up 22% year-over-year, and $631.4 million for the full year 2024, reflecting an 11% increase compared to the previous year. This robust financial performance was underpinned by strong operational execution and strategic acquisitions, such as the acquisition of Ironshore Therapeutics and its lead medicine, Jornay APM, establishing a presence in the neuropsychiatry market.

Jornay APM, a highly differentiated ADHD medication, demonstrated remarkable growth, with prescriptions surging 29% year-over-year and 11% quarter-over-quarter in Q4. Collegium is committed to maximizing Jornay's potential through targeted investments in awareness campaigns and expanded sales force initiatives, positioning it as a key growth driver for the company.

Furthermore, Collegium's pain portfolio, comprising BELBUCA, Extansa, and Nucynta, generated substantial revenue growth, underscoring the strength and durability of this franchise. The company's strategic initiatives, including extending projected exclusivity for Nucynta to July 2027, reinforce the portfolio's longevity and profitability.

Looking ahead, Collegium's priorities include driving significant growth in Jornay APM, maximizing the pain portfolio's potential, and strategically deploying capital through business development opportunities and share repurchases. The company's strong financial position, with net leverage expected to be less than one time by the end of 2025, provides flexibility for value-creating investments and shareholder-friendly initiatives.